Sessioni Poster

PHARMACOVIGILANCE

26/10/2017 / 19.00 - 21.00
4Occurrence of Liver Injury with drugs used for Multiple Sclerosis: signals emerging from the FDA Adverse Event Reporting System (FAERS)
1)Antonazzo IC. 2)Raschi E. 3)Forcesi E. 4)Poluzzi E. 5)De ponti F.
10ANALYSIS OF THE ADVERSE DRUG REACTIONS FOR FINGOLIMOD IN THE POST-MARKETING PHASE
1)Auricchio F. 2)Scavone C. 3)Cimmaruta D. 4)Larato A. 5)Fiorentino S. 6)Rossi F. 7)Capuano A.
11SAFETY OF NEW DIRECT-ACTING ANTIVIRALS (DAAS): DOES CARDIAC TOXICITY REPRESENT A REAL WARNING?
1)Bertini M. 2)Brusco S. 3)Cantile C. 4)Larato A. 5)Di mauro G. 6)Sportiello L. 7)Rossi F. 8)Capuano A.
23ESTIMATING INCIDENCE RATES OF ADVERSE EVENTS OF CHOLINESTERASE INHIBITORS IN ALZHEIMER'S DISEASE PATIENTS USING SPONTANEOUSLY REPORTING DATA.
1)Brusco S. 2)Bertini M. 3)Cantile C. 4)Larato A. 5)Rafaniello C. 6)Rossi F. 7)Capuano A.
24ROSACEA DURING FINGOLIMOD THERAPY IN MULTIPLE SCLEROSIS: A CASE SERIES
1)Brusco S. 2)Bertini M. 3)Rafaniello C. 4)Bisecco A. 5)Gallo A. 6)Capuano A.
26LONG TERM DRUG SAFETY IN CHILDREN: ANALYSIS ON SPONTANEOUS REPORTING SYSTEM OF SUSPECTED ADVERSE DRUG REACTIONS WITHIN MUSIC PROJECT
1)Ferrajolo C.. 2)Trifiro' G.. 3)Cimmaruta D.. 4)Ientile V.. 5)Moretti U.. 6)Sottosanti L.. 7)Rossi F.. 8)Capuano A..
29On the possible relationship between narcolepsy and vaccines: the analysis of AEFI reports from the VAERS database
1)Carnovale C. 2)Peeters G. 3)Gentili M. 4)Stella F. 5)Antoniazzi S. 6)Pozzi M. 7)Clementi E. 8)Radice S.
36Increasing trend in admission rates and costs for acute diverticulitis during 2005-2015: real-life data from the Abruzzo Region.
1)Cammarota S. 2)Citarella A. 3)Manzoli L. 4)Flacco ME. 5)Cuomo R.
48EVALUATION OF HEALTH DIRECT COSTS ASSOCIATED WITH THE USE OF BIOSIMILAR AND ORIGINATOR ERYTHROPOIESIS STIMULATING AGENTS (ESAS): AN ITALIAN, MULTI-REGIONAL, POPULATION BASED STUDY
1)Formica D. 2)Ingrasciotta Y. 3)Giorgianni F. 4)Aliquò G. 5)Chinellato A. 6)Tari D. 7)Gini R. 8)Pastorello M. 9)Scondotto S. 10)Cananzi P. 11)Traversa G. 12)Gennazzani A. 13)Trifirò G.
53MARKAR survey: influence of direct antiviral drugs in patients with hepatitis C virus infection
1)Gentili M. 2)Magni C. 3)Carnovale C. 4)Landonio S. 5)Schiavini M. 6)Niero F. 7)Rizzardini G. 8)Clementi E. 9)Radice S.
55WHAT IS THE EFFECT OF RISK MINIMIZATION MEASURES ON THE RISK OF ANTIPSYCHOTIC-ASSOCIATED STROKE IN ELDERLY PERSONS?
1)Giorgianni F. 2)Sultana J. 3)Tillati S. 4)Sturkenboom M. 5)Trifirò G.
64Risk of bone fractures among users of oral anticoagulants: an administrative database cohort study
1)Lucenteforte E. 2)Bettiol A. 3)Lombardi N. 4)Mugelli A. 5)Vannacci A.
67ATYPICAL SYMPTOMS OF TRAMADOL WITHDRAWAL: A CASE REPORT
1)Manzo V.. 2)Iannaccone T.. 3)D'amore C.. 4)Petrocelli A.. 5)Piscitelli A.. 6)Costantino M.. 7)Filippelli A.. 8)Conti V..
73HOSPICE PALLIATIVE CARE MEDICATION USE: AN ITALIAN REGIONAL STUDY
1)Penco I. 2)Mores N. 3)Bordin F.. 4)Turriziani A.. 5)Ginobbi P. 6)Proli E.
89DRUG-INDUCED KOUNIS SYNDROME: INSIGHTS FROM COMBINED LITERATURE REVIEW AND ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM
1)Raschi E. 2)Fertonani affini L. 3)Forcesi E. 4)Diemberger I. 5)Poluzzi E. 6)De ponti F.
93NSAIDs utilization in a large cohort of Italian elderly in secondary prevention for cerebro/cardiovascular disease
1)Roberto G. 2)Bartolini C. 3)Rea F. 4)Onder G. 5)Vitale C. 6)Trifirò G. 7)Kirchmayer U. 8)Chinellato A. 9)Lucenteforte E. 10)Corrao G. 11)Mugelli A. 12)Lapi F. 13)Gini R. 14)I-grade investigators.
106In search of biological substantiation through literature review and in silico analyses: the case of antipsychotic-associated pneumonia
1)Sultana J. 2)Crisafulli C. 3)Mestres J. 4)Garcia-serna R. 5)Calabro' M. 6)Trifiro' G.
110GENDER SPECIFIC DRUG USE IN PEDIATRICS: REAL WORLD DATA ANALYSIS ON BEHALF OF MUSIC PROJECT
1)Ferrajolo C.. 2)Giorgianni F.. 3)Aliquo' G.. 4)Ientile V.. 5)Tari M.. 6)Rossi F.. 7)Capuano A.. 8)Trifiro' G..
113A prospective observational study to reduce medication errors in hospital
1)Viola E. 2)Magro L. 3)Verlato G. 4)Finocchio E. 5)Bosello O. 6)Lechi A. 7)Leone R. 8)Velo GP.
119The importance of Integrated Care in the management of chronic disease. Patient Support Programs linked to drugs as tools for assistance and sources of pharmacovigilance data.
1)Angelini J. 2)Fiorentino M. 3)Pani A. 4)Nunnari P. 5)Rucci F. 6)Marino R. 7)Scaglione F. 8)Scatigna M.
124VIGINETWORK: A COMMUNITY PHARMACIES-NETWORK ON PHARMACOVIGILANCE IN VENETO REGION
1)Magro L. 2)Viola E. 3)Lora R. 4)Arzenton E. 5)Opri S. 6)Gonella L. 7)Stoppa G. 8)Moretti U. 9)Leone R.
133Safety profile of antipsychotic drugs: an Analysis of Sicilian Region Spontaneous Reporting System
1)M.A. Barbieri 2)G. Migliardi 3)G. Cicala 4)M. Trombini 5)P.M. Cutroneo 6)E. Spina
145DRUGS - INDUCED DISSEMINATED INTRAVASCULAR COAGULATION: A PHARMACOEPIDEMIOLOGICAL STUDY BASED ON WHO DATABASE OF ADVERSE DRUG REACTIONS
1)Bonaldo G. 2)Rossi L. 3)Melis M. 4)Gasperoni L. 5)Grandi S. 6)Vaccheri A. 7)Motola D.
159AN ALTERNATIVE METHOD FOR EVALUATING SKIN SENSITIZING POTENTIAL OF CHEMICALS USING FORWARD SCATTER
1)Buzzella A. 2)Mazzini G. 3)Vicini R. 4)Angelinetta C. 5)Balestra B. 6)Pastoris O.
204A CLINICIAN NETWORK FOR SHARING PATIENT EXPERIENCES IN PHARMACOVIGILANCE: THE PHARMACOWIKILANCE PROJECT
1)Convertino I.. 2)Galiulo M.. 3)Capogrosso-sansone A.. 4)Marino A.. 5)Knezevic T.. 6)Pieroni S.. 7)De nes M.. 8)Blandizzi C.. 9)Tuccori M..
215Trends in Spontaneous Adverse Drug Reaction Reporting to a Regional Pharmacovigilance Centre (years 2014-2016)
1)Cutroneo PM. 2)Cananzi P. 3)Oteri A. 4)Minore C. 5)Morreale I. 6)Longo L. 7)Mansueto S. 8)Vitale D. 9)Spina E.
216ADVERSE DRUG REACTIONS ASSOCIATED WITH NEWER LONG-ACTING INJECTABLES ANTIPSYCHOTICS: AN ANALYSIS OF THE ITALIAN SPONTANEOUS REPORTING SYSTEM DATABASE
1)Cutroneo P.. 2)Barbieri M.. 3)Cicala G.. 4)Migliardi G.. 5)Marchione P.. 6)Biasotta A.. 7)Trifirò G.. 8)Spina E..
224ADVERSE DRUG REACTIONS WITH BIOLOGICAL DRUGS IN RHEUMATOLOGY AND DERMATOLOGY UNITS
1)De fina M. 2)Palleria C. 3)Bennardo L. 4)Vona A. 5)Bottoni U. 6)L'Andolina M. 7)Valenti G. 8) D'Amico D. 9)Russo E. 10)De Sarro G.
226TREND OF ADVERSE DRUG REACTION REPORTING IN CALABRIA ACROSS THE PERIOD 2011-2016: WHICH IMPACT BY THE NEW EUROPEAN PHARMACOVIGILANCE LEGISLATION?
1)Leporini C. 2)Palleria C. 3)Leo A. 4)Lucia M. 5)Florio L. 6)Sorrentino A. 7)Piro B. 8)Costantino D. 9)Russo E. 10)De sarro G.
227ADVERSE DRUG REACTIONS BY BIOLOGICAL DRUGS IN GASTROENTEROLOGY UNITS
1)Palleria C. 2)De sarro G. 3)Bennardo L. 4)Luzza F. 5)Larussa T. 6)Doldo P. 7)Spagnuolo R. 8)Rodinò S. 9)Russo E.
228SPRUE-LIKE ENTEROPATHY ASSOCIATED WITH OLMESARTAN
1)Deidda A. 2)Pisanu C. 3)Arcadu F. 4)Derudas M. 5)Chillotti C. 6)Garau D. 7)Stochino ME.
229FREQUENCY AND CHARACTERISTICS OF ADVERSE DRUG REACTIONS TO ANTINEOPLASTIC AND IMMUNOMODULATORY MEDICATIONS IN THE METROPOLITAN AREA OF FLORENCE (ITALY)
1)Del lungo M. 2)Galloni C. 3)De angelis A. 4)Parrilli M. 5)Bettiol A. 6)Lombardi N. 7)Mugelli A. 8)Vannacci A.
270ADVERSE DRUG REACTIONS IN ONCOLOGY: INTENSIVE MONITORING PROGRAM ON DRUG TOXICITY OF BIOTECHNOLOGICAL MEDICATIONS AND TARGET THERAPIES IN ONCOLOGIC PATIENTS - THE ALEXANDROS OBSERVATIONAL STUDY
1)Galiulo M.. 2)Convertino I.. 3)Blandizzi C.. 4)Tassi R.. 5)Diacciati S.. 6)Nobili S.. 7)Capogrosso sansone A.. 8)Marino A.. 9)Mini E.. 10)Mazzei T.. 11)Vannacci A.. 12)Parrilli M.. 13)Corona T.. 14)Tuccori M..
283ADVERSE DRUG REACTIONS IN EMERGENCY DEPARTMENTS: A PROSPECTIVE 1-YEAR CHARACTERIZATION IN SICILY
1)Mocciaro E. 2)Lo giudice I. 3)Giardina C. 4)Santangelo A. 5)Spina E. 6)Arcoraci V. 7)Cutroneo PM.
290Off-label drug use and safety of intravitreal anti-VEGF: data from Registries and Pharmacovigilance Network
1)Gozzo L. 2)Benfatto G. 3) Longo L. 4) Mansueto S. 5) Vitale D.C. 6) Lazzara A. 7) Drago F.
291Off-label drug use at the Policlinic-University Hospital of Catania, from 2012 to 2015: Focus on intra-ocular use of mitomycin
1)Gozzo L. 2)Benfatto G. 3) Longo L. 4) Mansueto S. 5) Vitale D.C. 6) Lazzara A. 7) Drago F.
292Off-label drug use at the University Hospital of Catania: 2016 update
1)Gozzo L.. 2)Benfatto G.. 3)Longo L.. 4)Mansueto S.. 5)Vitale DC. 6)Lazzara A.. 7)Drago F..
293Reporting of adverse drug reactions by nursing and medicine students in Italy: a questionnaire-based study
1)Grandi S. 2)Nappo A. 3)Gasperoni L. 4)Bonaldo G. 5)Scalorbi S. 6)Di lorenzo D. 7)Vaccheri A. 8)Motola D.
303REAL-LIFE SAFETY AND EFFECTIVENESS OF APIXABAN IN PATIENTS WITH NON VALVULAR ATRIAL FIBRILLATION
1)Verdecchia P.. 2)Lanati E.. 3)Verdini V.. 4)Corrao G.. 5)Scotti L.. 6)Airoldi C.. 7)Iorio A..
304REtrospective study on ItaliaN ADPKD disease management cost
1)Lanati EP. 2)Marcelli A.. 3)Ruggeri M.. 4)Rolli FR. 5)Caramuscio R.. 6)Ballantini F.. 7)Scolari F..
326PHYTO.VIG.GEST: "VIGILANCE ON USE OF DRUGS, HERBAL PRODUCTS AND FOOD SUPPLEMENTS DURING PREGNANCY: FOCUS ON FOSFOMYCIN".
1)Mannucci C. 2)Dante G. 3)Miroddi M. 4)Facchinetti F. 5)D'anna R. 6)Santamaria A. 7)Calapai F. 8)Lenti MC. 9)Perone M. 10)Navarra M. 11)Calapai G.
354CARDIOVASCULAR SAFETY OF MACROLIDE AND FLUOROQUINOLONE ANTIBIOTICS: AN ANALYSIS OF THE WHO DATABASE OF ADVERSE DRUG REACTIONS
1)Andriani L.. 2)Melis M.. 3)Grandi S.. 4)Bonaldo G.. 5)Motola D.. 6)Vaccheri A..
376Use of electronic health records to study the real world utilization of antineoplastic drugs for the treatment of lung cancer at the University Hospital of Siena
Francesco Pellicano, Andrea Spini, Sandra Donnini, Silvano Giorgi, Claudia Bartolini, Rosa Gini, Andrea Vannucci, Fabio Voller, Giuseppe Roberto, Marina Ziche.
399Six-month levetiracetam treatment in epileptic patients after branded-to-generic switch; a community-based retrospective study
1)Rigamonti AE. 2)Group of ainat neurologists .
402Utilization of biological drugs for the treatment of rheumatoid arthritis in Tuscany, Italy
1)Roberto G. 2)Bardelli F. 3)Bartolini C. 4)Gini R.
410MONITORING SAFETY AND USE OF OLD AND NEW THERAPIES FOR TYPE 2 DIABETIC PATIENTS IN CALABRIA: A TWO-YEAR (2013-2016) ANALYSIS
1)Leporini C. 2)Piro R. 3)Maida F. 4)Citraro R. 5)Mangano G. 6)De sarro C. 7)Palleria C. 8)Artudi F. 9)Pavia M. 10)Russo E.
438INTENSIVE MONITORING PROGRAM OF TERATOGEN AND NON-TERATOGEN RISK OF DRUGS DURING PREGNANCY: THE STORK PROJECT
1)Tuccori M.. 2)Convertino I.. 3)Galiulo M.. 4)Capogrosso sansone A.. 5)Mantarro S.. 6)Marino A.. 7)Vannacci A.. 8)Parrilli M.. 9)Corona T.. 10)Blandizzi C..